Epigenetics represents the impact of the combination of genetic, lifestyle and environmental factors on humans. We utilise EpiSwitch™, a proprietary biomarker discovery platform licensed from our AIM listed shareholder Oxford Biodynamics Plc.
When someone asked my husband how he is doing in light of COVID-19, Todd replied, “Our life isn’t that much different. Now everyone else is dealing with what we have
Oxford BioDynamics’ EpiSwitchTM platform is the first industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs
One of my biggest concerns is how my husband’s ALS will affect our children. They were both under 5 when Todd was diagnosed and while they are growing up, their
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of biomarkers, based on regulatory 3D genome architecture, using its liquid biopsy platform EpiSwitchTM, has today announced that
EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’ (“CCSs”). CCSs can provide a compelling, stable framework
An abundance of events are afoot around the world to mark Rare Disease Day 2020 on Feb. 29. The activities are focused on heightening awareness about rare diseases and the hundreds of
Data yielded by application of OBD’s 3D genome architecture technology platform, EpiSwitch™ was presented at The Society for Immunotherapy of Cancer’s 34th Annual Meeting. The poster presentations indicate that the biomarkers
Today, at a European Parliament lunch debate hosted by Christophe Hansen MEP (Luxembourg), Alzheimer Europe launched a new report presenting the findings of its collaborative analysis of recent prevalence studies
Oxford BioDynamics Plc (LON:OBD), a biotechnology company focused on the discovery and development of biomarkers based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, today
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
